DE10000333A1 - Pharmazeutische Zusammensetzung zur transdermalen Verabreichung von Hormonen mit einem permeationsverbessernden Zusatzstoff - Google Patents

Pharmazeutische Zusammensetzung zur transdermalen Verabreichung von Hormonen mit einem permeationsverbessernden Zusatzstoff

Info

Publication number: DE10000333A1
Authority: DE; Germany
Prior art keywords: composition according; estradiol; hormone; skin; radicals
Prior art date: 2000-01-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

DE2000100333

Other languages

German (de)

English (en)

Inventor

Achim Berthold

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

LTS Lohmann Therapie Systeme AG

Original Assignee

LTS Lohmann Therapie Systeme AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-01-07

Filing date

2000-01-07

Publication date

2001-07-19

2000-01-07 Application filed by LTS Lohmann Therapie Systeme AG filed Critical LTS Lohmann Therapie Systeme AG

2000-01-07 Priority to DE2000100333 priority Critical patent/DE10000333A1/de

2000-12-23 Priority to PCT/EP2000/013268 priority patent/WO2001049273A2/de

2000-12-23 Priority to AU23698/01A priority patent/AU2369801A/en

2001-01-05 Priority to ARP010100041A priority patent/AR026797A1/es

2001-07-19 Publication of DE10000333A1 publication Critical patent/DE10000333A1/de

Status Withdrawn legal-status Critical Current

Links

229940088597 hormone Drugs 0.000 title claims abstract description 35
239000005556 hormone Substances 0.000 title claims abstract description 35
239000000654 additive Substances 0.000 title claims abstract description 13
230000000996 additive effect Effects 0.000 title claims abstract description 13
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 5
239000011159 matrix material Substances 0.000 claims abstract description 33
239000000203 mixture Substances 0.000 claims abstract description 28
125000000524 functional group Chemical group 0.000 claims abstract description 7
RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims abstract description 4
125000001183 hydrocarbyl group Chemical group 0.000 claims abstract 4
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 39
229960005309 estradiol Drugs 0.000 claims description 28
239000000583 progesterone congener Substances 0.000 claims description 27
239000000262 estrogen Substances 0.000 claims description 25
229940011871 estrogen Drugs 0.000 claims description 25
229930182833 estradiol Natural products 0.000 claims description 21
230000001070 adhesive effect Effects 0.000 claims description 14
239000000853 adhesive Substances 0.000 claims description 13
230000001225 therapeutic effect Effects 0.000 claims description 11
IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 claims description 10
229960001652 norethindrone acetate Drugs 0.000 claims description 10
238000004519 manufacturing process Methods 0.000 claims description 8
238000011282 treatment Methods 0.000 claims description 6
229920000642 polymer Polymers 0.000 claims description 5
239000003270 steroid hormone Substances 0.000 claims description 5
WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims description 4
DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 claims description 4
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
-1 ethi steron Chemical compound 0.000 claims description 4
229960004400 levonorgestrel Drugs 0.000 claims description 4
229940053934 norethindrone Drugs 0.000 claims description 4
VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims description 4
238000011321 prophylaxis Methods 0.000 claims description 4
239000002552 dosage form Substances 0.000 claims description 3
229920000058 polyacrylate Polymers 0.000 claims description 3
ISHXLNHNDMZNMC-VTKCIJPMSA-N (3e,8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C\1 ISHXLNHNDMZNMC-VTKCIJPMSA-N 0.000 claims description 2
BFPYWIDHMRZLRN-SWBPCFCJSA-N (8r,9s,13s,14s,17s)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SWBPCFCJSA-N 0.000 claims description 2
229930182834 17alpha-Estradiol Natural products 0.000 claims description 2
DBPWSSGDRRHUNT-UHFFFAOYSA-N 17alpha-hydroxy progesterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)(O)C1(C)CC2 DBPWSSGDRRHUNT-UHFFFAOYSA-N 0.000 claims description 2
VOXZDWNPVJITMN-SFFUCWETSA-N 17α-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-SFFUCWETSA-N 0.000 claims description 2
NVUUMOOKVFONOM-GPBSYSOESA-N 19-Norprogesterone Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 NVUUMOOKVFONOM-GPBSYSOESA-N 0.000 claims description 2
ATXHVCQZZJYMCF-XUDSTZEESA-N Allylestrenol Chemical compound C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)CC=C)[C@@H]4[C@@H]3CCC2=C1 ATXHVCQZZJYMCF-XUDSTZEESA-N 0.000 claims description 2
UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 claims description 2
YNVGQYHLRCDXFQ-XGXHKTLJSA-N Lynestrenol Chemical compound C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 YNVGQYHLRCDXFQ-XGXHKTLJSA-N 0.000 claims description 2
UDKABVSQKJNZBH-DWNQPYOZSA-N Melengestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(=C)[C@](OC(=O)C)(C(C)=O)[C@@]1(C)CC2 UDKABVSQKJNZBH-DWNQPYOZSA-N 0.000 claims description 2
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
229960002692 allylestrenol Drugs 0.000 claims description 2
229960003996 chlormadinone Drugs 0.000 claims description 2
VUHJZBBCZGVNDZ-TTYLFXKOSA-N chlormadinone Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 VUHJZBBCZGVNDZ-TTYLFXKOSA-N 0.000 claims description 2
229920001577 copolymer Polymers 0.000 claims description 2
229960004976 desogestrel Drugs 0.000 claims description 2
RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 claims description 2
229940012028 ethynodiol diacetate Drugs 0.000 claims description 2
ONKUMRGIYFNPJW-KIEAKMPYSA-N ethynodiol diacetate Chemical compound C1C[C@]2(C)[C@@](C#C)(OC(C)=O)CC[C@H]2[C@@H]2CCC3=C[C@@H](OC(=O)C)CC[C@@H]3[C@H]21 ONKUMRGIYFNPJW-KIEAKMPYSA-N 0.000 claims description 2
229910052736 halogen Inorganic materials 0.000 claims description 2
150000002367 halogens Chemical class 0.000 claims description 2
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 2
229960002899 hydroxyprogesterone Drugs 0.000 claims description 2
229950000801 hydroxyprogesterone caproate Drugs 0.000 claims description 2
229960001910 lynestrenol Drugs 0.000 claims description 2
229960004805 melengestrol Drugs 0.000 claims description 2
IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 claims description 2
229960001390 mestranol Drugs 0.000 claims description 2
238000000034 method Methods 0.000 claims description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
229910052757 nitrogen Inorganic materials 0.000 claims description 2
229960002667 norelgestromin Drugs 0.000 claims description 2
229960000417 norgestimate Drugs 0.000 claims description 2
KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 claims description 2
229910052698 phosphorus Inorganic materials 0.000 claims description 2
239000011574 phosphorus Substances 0.000 claims description 2
229920002959 polymer blend Polymers 0.000 claims description 2
229960001424 quinestrol Drugs 0.000 claims description 2
PWZUUYSISTUNDW-VAFBSOEGSA-N quinestrol Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@]4(O)C#C)C)CC2=CC=3OC1CCCC1 PWZUUYSISTUNDW-VAFBSOEGSA-N 0.000 claims description 2
238000006467 substitution reaction Methods 0.000 claims description 2
229910052717 sulfur Inorganic materials 0.000 claims description 2
239000011593 sulfur Substances 0.000 claims description 2
QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 claims 1
230000002378 acidificating effect Effects 0.000 claims 1
150000001338 aliphatic hydrocarbons Chemical class 0.000 claims 1
239000011248 coating agent Substances 0.000 claims 1
238000000576 coating method Methods 0.000 claims 1
238000001035 drying Methods 0.000 claims 1
SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 claims 1
238000010438 heat treatment Methods 0.000 claims 1
238000010030 laminating Methods 0.000 claims 1
229960002985 medroxyprogesterone acetate Drugs 0.000 claims 1
PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 claims 1
238000004080 punching Methods 0.000 claims 1
210000003491 skin Anatomy 0.000 description 27
239000010410 layer Substances 0.000 description 18
239000013543 active substance Substances 0.000 description 10
239000004480 active ingredient Substances 0.000 description 9
238000000338 in vitro Methods 0.000 description 9
229940079593 drug Drugs 0.000 description 8
239000003814 drug Substances 0.000 description 8
229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 8
229920006267 polyester film Polymers 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
230000008901 benefit Effects 0.000 description 6
230000000694 effects Effects 0.000 description 6
210000002615 epidermis Anatomy 0.000 description 6
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 5
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 4
239000003961 penetration enhancing agent Substances 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 3
239000002313 adhesive film Substances 0.000 description 3
238000009792 diffusion process Methods 0.000 description 3
239000003623 enhancer Substances 0.000 description 3
239000003163 gonadal steroid hormone Substances 0.000 description 3
230000003054 hormonal effect Effects 0.000 description 3
206010020718 hyperplasia Diseases 0.000 description 3
210000004379 membrane Anatomy 0.000 description 3
239000012528 membrane Substances 0.000 description 3
230000036470 plasma concentration Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 2
DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 2
229920002367 Polyisobutene Polymers 0.000 description 2
MTHSVFCYNBDYFN-UHFFFAOYSA-N anhydrous diethylene glycol Natural products OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
229920005601 base polymer Polymers 0.000 description 2
239000013065 commercial product Substances 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
229960003399 estrone Drugs 0.000 description 2
238000010579 first pass effect Methods 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
150000002430 hydrocarbons Chemical group 0.000 description 2
230000035515 penetration Effects 0.000 description 2
239000002985 plastic film Substances 0.000 description 2
229920006255 plastic film Polymers 0.000 description 2
229920005591 polysilicon Polymers 0.000 description 2
229920000346 polystyrene-polyisoprene block-polystyrene Polymers 0.000 description 2
229960003387 progesterone Drugs 0.000 description 2
239000000186 progesterone Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
VTDOEFXTVHCAAM-UHFFFAOYSA-N 4-methylpent-3-ene-1,2,3-triol Chemical compound CC(C)=C(O)C(O)CO VTDOEFXTVHCAAM-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
206010013496 Disturbance in attention Diseases 0.000 description 1
241001077885 Gesta Species 0.000 description 1
208000008454 Hyperhidrosis Diseases 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
206010027304 Menopausal symptoms Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
206010040799 Skin atrophy Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
208000001871 Tachycardia Diseases 0.000 description 1
230000009471 action Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000032683 aging Effects 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
230000036765 blood level Effects 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000036576 dermal application Effects 0.000 description 1
GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
210000004696 endometrium Anatomy 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
229960003575 estradiol acetate Drugs 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000004744 fabric Substances 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
238000011010 flushing procedure Methods 0.000 description 1
230000004907 flux Effects 0.000 description 1
239000011888 foil Substances 0.000 description 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
230000030136 gastric emptying Effects 0.000 description 1
210000001156 gastric mucosa Anatomy 0.000 description 1
239000003292 glue Substances 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
231100000508 hormonal effect Toxicity 0.000 description 1
230000003581 hormone blood level Effects 0.000 description 1
238000002657 hormone replacement therapy Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000008991 intestinal motility Effects 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000007794 irritation Effects 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
150000003893 lactate salts Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000010871 livestock manure Substances 0.000 description 1
238000000691 measurement method Methods 0.000 description 1
229960004296 megestrol acetate Drugs 0.000 description 1
RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
230000005906 menstruation Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
239000011707 mineral Substances 0.000 description 1
DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
229940126701 oral medication Drugs 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000027758 ovulation cycle Effects 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
239000003973 paint Substances 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000012466 permeate Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
239000011241 protective layer Substances 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
230000035900 sweating Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000006794 tachycardia Effects 0.000 description 1
238000012549 training Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
229940070710 valerate Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DE2000100333 2000-01-07 2000-01-07 Pharmazeutische Zusammensetzung zur transdermalen Verabreichung von Hormonen mit einem permeationsverbessernden Zusatzstoff Withdrawn DE10000333A1 (de)

Priority Applications (4)

Application Number	Priority Date	Filing Date	Title
DE2000100333 DE10000333A1 (de)	2000-01-07	2000-01-07	Pharmazeutische Zusammensetzung zur transdermalen Verabreichung von Hormonen mit einem permeationsverbessernden Zusatzstoff
PCT/EP2000/013268 WO2001049273A2 (de)	2000-01-07	2000-12-23	Pharmazeutische zusammensetzung zur transdermalen verabreichung von hormonen mit einem permeationsverbessernden zusatzstoff
AU23698/01A AU2369801A (en)	2000-01-07	2000-12-23	Pharmaceutical composition for transdermally administering hormones with an additive that enhances permeation
ARP010100041A AR026797A1 (es)	2000-01-07	2001-01-05	Compuesto farmaceutico con un aditivo promotor de la permeacion para la administracion transdermal de hormonas.

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE2000100333 DE10000333A1 (de)	2000-01-07	2000-01-07	Pharmazeutische Zusammensetzung zur transdermalen Verabreichung von Hormonen mit einem permeationsverbessernden Zusatzstoff

Publications (1)

Publication Number	Publication Date
DE10000333A1 true DE10000333A1 (de)	2001-07-19

Family

ID=7626866

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE2000100333 Withdrawn DE10000333A1 (de)	2000-01-07	2000-01-07	Pharmazeutische Zusammensetzung zur transdermalen Verabreichung von Hormonen mit einem permeationsverbessernden Zusatzstoff

Country Status (4)

Country	Link
AR (1)	AR026797A1 (es)
AU (1)	AU2369801A (es)
DE (1)	DE10000333A1 (es)
WO (1)	WO2001049273A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2873371B1 (fr) *	2004-07-26	2008-07-04	Sod Conseils Rech Applic	Nouvelle methode de synthese de 2,5 dioxane 1,4 diones
DE102006050558B4 (de)	2006-10-26	2009-03-26	Lts Lohmann Therapie-Systeme Ag	Transdermales therapeutisches System enthaltend Norelgestromin zur Kontrazeption und Hormonsubstitution
DE102010004769A1 (de)	2009-07-08	2011-01-13	Kuchenbecker, Manfred, Dr.-Ing.	Reluktanzgenerator
US9284294B2 (en)	2012-02-09	2016-03-15	Novus International, Inc.	Functionalized polymer compositions
CN104754956B (zh)	2012-07-12	2017-11-17	诺华丝国际股份有限公司	用于保护生物活性剂的基质和层组合物
BR112016002609A2 (pt)	2013-08-09	2017-08-01	Chemours Co Fc Llc	composição para tratamento de pele e método para fabricação de uma composição
US10584306B2 (en)	2017-08-11	2020-03-10	Board Of Regents Of The University Of Oklahoma	Surfactant microemulsions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GR1002079B (en) *	1994-07-26	1995-12-05	Lavipharm A E	System of a special structure and composition for the rapid transdermal administration of oestrogens.
AU6032696A (en) *	1995-06-07	1996-12-30	Cygnus Therapeutic Systems	Pressure sensitive acrylate adhesive composition cross-linke d with aluminum acetylacetonate and containing a drug having a reactive aromatic hydroxyl group

2000
- 2000-01-07 DE DE2000100333 patent/DE10000333A1/de not_active Withdrawn
- 2000-12-23 AU AU23698/01A patent/AU2369801A/en not_active Abandoned
- 2000-12-23 WO PCT/EP2000/013268 patent/WO2001049273A2/de not_active Ceased
2001
- 2001-01-05 AR ARP010100041A patent/AR026797A1/es unknown

Also Published As

Publication number	Publication date
WO2001049273A3 (de)	2002-05-23
WO2001049273A2 (de)	2001-07-12
AU2369801A (en)	2001-07-16
AR026797A1 (es)	2003-02-26

Publication	Publication Date	Title
DE4336557C2 (de)	1997-07-17	Estradiolhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
DE3751447T2 (de)	1996-02-22	Transdermale östrogen-/progestin-Einheitsdosis, Kit zur Fertilitätskontrolle enthaltend diese Einheitsdosis.
EP0744944B1 (de)	1999-11-03	Transdermale therapeutische systeme enthaltend sexualsteroide
DE68926122T2 (de)	1996-12-19	Transdermale estrogen/progestin-dosiereinheit und system.
DE69901561T2 (de)	2002-10-10	Transdermales pflaster des matrixtyps für steroidhormone
EP0813865B1 (de)	2001-09-19	Wirkstoffpflaster
EP0356382B1 (de)	1994-02-16	Mehrschichtiges Pflaster
DE3222800C2 (es)	1989-03-16
EP0802789B1 (de)	1999-07-07	Estradiolhaltiges pflaster
DE19728517C2 (de)	1999-11-11	TTS zur Verabreichung von Sexualsteroidhormonen und Verfahren zu seiner Herstellung
EP1485072B1 (de)	2009-04-29	Hormonhaltiges transdermales therapeutisches system mit einem wirkstoffreservoir auf der basis von vinylacetat-vinylpyrrolidon-copolymer mit verbesserter kohäsion.
DE4241874A1 (de)	1994-06-16	Medizinisches Pflaster für die perkutane Verabreichung
EP1448175A1 (de)	2004-08-25	Steroidhormonhaltige transdermale therapeutische systeme enthaltend propylenglycolmonocaprylat
WO1994006436A1 (de)	1994-03-31	Dexpanthenol-haltiges pflaster zur transdermalen applikation von steroidhormonen
DE60101206T2 (de)	2004-09-02	Transdermale verabreichung von lasofoxifen
DE10000333A1 (de)	2001-07-19	Pharmazeutische Zusammensetzung zur transdermalen Verabreichung von Hormonen mit einem permeationsverbessernden Zusatzstoff
DE69530832T2 (de)	2004-04-22	Transdermales abgabesystem, das ein östrogen enthält
EP1093361B1 (de)	2003-05-02	Steroidhaltiges pflaster, verfahren zu seiner herstellung und verwendung
DE19546024C2 (de)	1998-09-10	Transdermale pharmazeutische Zubereitung und deren Herstellung
EP0744943A1 (de)	1996-12-04	Mittel zur transdermalen applikation enthaltend desogestrel
EP1761242A2 (de)	2007-03-14	Filmförmiges, oral zu verabreichendes arzneimittel, enthaltend estriol
DE10025970C2 (de)	2002-04-25	Estrogenhaltiges Pflaster mit einem Wirkstoffreservoir auf der Basis von Ethylcellulose und einem Ethylen-Vinylacetat-Vinylpyrrolidon-Copolymer und seine Verwendung
DE10025971B4 (de)	2004-09-02	Transdermales therapeutisches System in Plasterform mit verminderter Tendenz zur Wirkstoffkristallisation und seine Verwendung
WO1995020392A1 (de)	1995-08-03	MITTEL ZUR TRANSDERMALEN APPLIKATION ENTHALTEND 14α,17α-ETHANOESTRA-1,3,5(10)-TRIEN-3,17β-DIOL

Legal Events

Date	Code	Title	Description
2001-07-19	OP8	Request for examination as to paragraph 44 patent law
2002-12-19	8139	Disposal/non-payment of the annual fee